Eulàlia Olesti
Pompeu Fabra University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Eulàlia Olesti.
Neuropsychopharmacology | 2016
Esther Papaseit; Clara Pérez-Mañá; Julián-Andrés Mateus; Mitona Pujadas; Francina Fonseca; Marta Torrens; Eulàlia Olesti; Rafael de la Torre; Magí Farré
Mephedrone (4-methylmethcathinone) is a novel psychoactive substance popular among drug users because it displays similar effects to MDMA (3,4-methylenedioxymethamphetamine, ecstasy). Mephedrone consumption has been associated with undesirable effects and fatal intoxications. At present, there is no research available on its pharmacological effects in humans under controlled and experimental administration. This study aims to evaluate the clinical pharmacology of mephedrone and its relative abuse liability compared with MDMA. Twelve male volunteers participated in a randomized, double-blind, crossover, and placebo-controlled trial. The single oral dose conditions were: mephedrone 200 mg, MDMA 100 mg, and placebo. Outcome variables included physiological, subjective, and psychomotor effects, and pharmacokinetic parameters. The protocol was registered in ClinicalTrials.gov (NCT02232789). Mephedrone produced a significant increase in systolic and diastolic blood pressure, heart rate, and pupillary diameter. It elicited stimulant-like effects, euphoria, and well-being, and induced mild changes in perceptions with similar ratings to those observed after MDMA administration although effects peaked earlier and were shorter in duration. Maximal plasma concentration values for mephedrone and MDMA peaked at 1.25 h and 2.00 h, respectively. The elimination half-life for mephedrone was 2.15 h and 7.89 h for MDMA. In a similar manner to MDMA, mephedrone exhibits high abuse liability. Its earlier onset and shorter duration of effects, probably related to its short elimination half-life, could explain a more compulsive pattern of use as described by the users.
Drug Metabolism Reviews | 2016
Anna Boronat; Aristotelis Kotronoulas; Mitona Pujadas; Antoni Pastor; Eulàlia Olesti; Clara Pérez-Mañá; Olha Khymenets; Montserrat Fitó; Magí Farré; Rafael de la Torre
Abstract Hydroxytyrosol and tyrosol are dietary phenolic compounds present in virgin olive oil and wine. Both compounds are also endogenously synthesized in our body as byproducts of dopamine and tyramine metabolisms, respectively. Over the last decades, research into hydroxytyrosol and tyrosol has experienced an increasing interest due to the role that these compounds may play in the prevention of certain pathologies (e.g. cardiovascular, metabolic, neurodegenerative diseases and cancer). The translation of promising in vitro and in vivo biological effects from preclinical studies to the context of human disease prevention initially depends on whether the dose ingested becomes available at the site of action. In this regard, information regarding the bioavailability and metabolic disposition of hydroxytyrosol and tyrosol is of most importance to evaluate the impact they may have on human health. In this review, we discuss and summarize the state of the art of the scientific evidence regarding the processes of absorption, distribution, metabolism and excretion of both hydroxytyrosol and tyrosol. We also examine the impact of these compounds and their metabolites on biological activity in terms of beneficial health effects. Finally, we evaluate the different analytical approaches that have been developed to measure the plasma and urinary levels of hydroxytyrosol, tyrosol and their metabolites.
Journal of Chromatography A | 2016
Antoni Pastor; Eulàlia Olesti; Mitona Pujadas; Clara Pérez-Mañá; Olha Khymenets; Montserrat Fitó; María-Isabel Covas; Rosa Solà; Maria-José Motilva; Magí Farré; Rafael de la Torre
Hydroxytyrosol (HT) from olive oil, a potent bioactive molecule with health benefits, has a poor bioavailability, its free form (free HT) being undetectable so far. This fact leads to the controversy whether attained HT concentrations after olive oil polyphenol ingestion are too low to explain the observed biological activities. Due to this, an analytical methodology to determine free HT in plasma is crucial for understanding HT biological activity. Plasma HT instability and low concentrations have been major limitations for its quantification in clinical studies. Here, we describe a method to detect and quantify free HT in human plasma by using liquid chromatography coupled to tandem mass spectrometry. The method encompasses different steps of sample preparation including plasma stabilization, protein precipitation, selective derivatization with benzylamine, and purification by solid-phase extraction. A high sensitivity (LOD, 0.3ng/mL), specificity and stability of HT is achieved following these procedures. The method was validated and its applicability was demonstrated by analyzing human plasma samples after olive oil intake. A pharmacokinetic comparison was performed measuring free HT plasma concentrations following the intake of 25mL of ordinary olive oil (nearly undetectable concentrations) versus an extra-virgin olive oil (Cmax=4.40ng/mL). To our knowledge, this is the first time that an analytical procedure for quantifying free HT in plasma after olive oil dietary doses has been reported. The present methodology opens the door to a better understanding of the relationship between HT plasma concentrations and its beneficial health effects.
Talanta | 2019
Eulàlia Olesti; Alex Gomez-Gomez; Johannes G. Ramaekers; Rafael de la Torre; Oscar J. Pozo
Neurotransmitters are signaling molecules, playing key roles in neuronal communications in the brain. Drug induced changes in neurotransmitters and other brain metabolite concentration may be used to characterize drugs according to their targeted metabolomics profile. Here, we report the development and validation of a straightforward liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous quantification of 16 endogenous small polar compounds in rat plasma and brain homogenates. The method enables the quantification of the neurotransmitters γ-aminobutyric acid, glutamate, acetylcholine and adenosine, as well as choline, glutamine, acetylcarnitine, carnitine, creatine, creatinine, valine, leucine, isoleucine, phenylalanine, tyrosine and tryptophan. After optimizing the sample preparation, chromatographic and spectrometric conditions, the method was successfully validated using the standard addition approach and a hydrophilic interaction chromatography (HILIC) with an amide column. The method was shown to be linear (r > 0.99) as all the compounds were within the ±25% values of intra and inter-day precision and accuracy acceptance. A matrix effect was corrected with the use of 10 isotopically labelled internal standards and the compound stability was evaluated for all compounds. Relevant exaltation of choline (in plasma) and creatinine (in brain) were solved with -20 °C conditions. The applicability of the method was tested by evaluating brain alterations in the concentrations of neurotransmitters and related compounds after the administration of two psychostimulant drugs of abuse (cocaine and methylenedioxypyrovalerone) to rats. A neuro-metabolic fingerprint of each drug was obtained that reflected their pharmacological profile. Altogether, this methodology presents a valuable targeted metabolomics tool for basic and clinical research studies.
Journal of Analytical Toxicology | 2016
Eulàlia Olesti; Mitona Pujadas; Esther Papaseit; Clara Pérez-Mañá; Oscar J. Pozo; Magí Farré; Rafael de la Torre
Current Pharmaceutical Design | 2018
Esther Papaseit; Eulàlia Olesti; Rafael de la Torre; Marta Torrens; Magí Farré
Aaps Journal | 2017
Eulàlia Olesti; Magí Farré; Esther Papaseit; Aristotelis Krotonoulas; Mitona Pujadas; Rafael de la Torre; Oscar J. Pozo
European Psychiatry | 2016
Magí Farré; Clara Pérez-Mañá; E. de Souza; J. Mateus; E. Theunisen; Kim P. C. Kuypers; Jan Ramaekers; Francisco Antonio Helfenstein Fonseca; Marta Torrens; Eulàlia Olesti; R. de la Torre; Esther Papaseit
Psychopharmacology | 2018
E Haijen; Magí Farré; R. de la Torre; A.M. Pastor; Eulàlia Olesti; N. Pizarro; Johannes G. Ramaekers; Kim P. C. Kuypers
Drug and Alcohol Dependence | 2017
Magí Farré; Esther Papaseit; Clara Pérez-Mañá; Eliza de Souza Fernandes; Julian Farré Mateus; Eulàlia Olesti; Kim P. C. Kuypers; Eef Theunisen; Francina Fonseca; Marta Torrens; Jan Ramaekers; Rafael de la Torre